Camurus AB (publ) (CAMRF)
USD 59.98
(0.01%)
USD 59.98
(0.01%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.9 Billion SEK | 46.14% |
| 2022 | 1.3 Billion SEK | 20.67% |
| 2021 | 1.08 Billion SEK | 3.62% |
| 2020 | 1.04 Billion SEK | 35.24% |
| 2019 | 772.04 Million SEK | 111.68% |
| 2018 | 364.72 Million SEK | -23.37% |
| 2017 | 475.93 Million SEK | -25.61% |
| 2016 | 639.77 Million SEK | -21.63% |
| 2015 | 816.34 Million SEK | 293.1% |
| 2014 | 207.66 Million SEK | 85.99% |
| 2013 | 111.65 Million SEK | 94.51% |
| 2012 | 57.4 Million SEK | -34.65% |
| 2011 | 87.84 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.06 Billion SEK | 60.43% |
| 2024 Q2 | 3.43 Billion SEK | 12.13% |
| 2023 Q4 | 1.9 Billion SEK | 3.59% |
| 2023 FY | 1.9 Billion SEK | 46.14% |
| 2023 Q1 | 1.34 Billion SEK | 3.41% |
| 2023 Q2 | 1.77 Billion SEK | 31.38% |
| 2023 Q3 | 1.84 Billion SEK | 3.84% |
| 2022 Q1 | 1.09 Billion SEK | 0.96% |
| 2022 FY | 1.3 Billion SEK | 20.67% |
| 2022 Q3 | 1.23 Billion SEK | 8.9% |
| 2022 Q4 | 1.3 Billion SEK | 5.83% |
| 2022 Q2 | 1.13 Billion SEK | 3.7% |
| 2021 Q4 | 1.08 Billion SEK | 3.43% |
| 2021 Q3 | 1.04 Billion SEK | 0.03% |
| 2021 FY | 1.08 Billion SEK | 3.62% |
| 2021 Q1 | 1.02 Billion SEK | -1.39% |
| 2021 Q2 | 1.04 Billion SEK | 1.57% |
| 2020 Q3 | 989.62 Million SEK | 36.81% |
| 2020 FY | 1.04 Billion SEK | 35.24% |
| 2020 Q2 | 723.37 Million SEK | -0.95% |
| 2020 Q1 | 730.35 Million SEK | -5.4% |
| 2020 Q4 | 1.04 Billion SEK | 5.5% |
| 2019 Q3 | 565.43 Million SEK | -9.55% |
| 2019 FY | 772.04 Million SEK | 111.68% |
| 2019 Q4 | 772.04 Million SEK | 36.54% |
| 2019 Q2 | 625.16 Million SEK | -11.12% |
| 2019 Q1 | 703.4 Million SEK | 92.86% |
| 2018 Q4 | 364.72 Million SEK | -17.38% |
| 2018 FY | 364.72 Million SEK | -23.37% |
| 2018 Q1 | 435.87 Million SEK | -8.42% |
| 2018 Q2 | 490.13 Million SEK | 12.45% |
| 2018 Q3 | 441.45 Million SEK | -9.93% |
| 2017 FY | 475.93 Million SEK | -25.61% |
| 2017 Q1 | 597.59 Million SEK | -6.59% |
| 2017 Q2 | 570.4 Million SEK | -4.55% |
| 2017 Q3 | 520.41 Million SEK | -8.76% |
| 2017 Q4 | 475.93 Million SEK | -8.55% |
| 2016 Q4 | 639.77 Million SEK | -1.42% |
| 2016 Q2 | 660.26 Million SEK | -2.36% |
| 2016 FY | 639.77 Million SEK | -21.63% |
| 2016 Q3 | 648.97 Million SEK | -1.71% |
| 2016 Q1 | 676.18 Million SEK | -17.17% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q4 | 816.34 Million SEK | 288.33% |
| 2015 Q3 | 210.22 Million SEK | 0.0% |
| 2015 FY | 816.34 Million SEK | 293.1% |
| 2014 Q4 | 207.66 Million SEK | 0.0% |
| 2014 FY | 207.66 Million SEK | 85.99% |
| 2013 FY | 111.65 Million SEK | 94.51% |
| 2012 FY | 57.4 Million SEK | -34.65% |
| 2011 FY | 87.84 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 10.55 Million USD | -17976.748% |
| BioStem Technologies, Inc. | 14.56 Million USD | -13002.897% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -1365.179% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -6727.297% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -539415.917% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -277406.742% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -97327.776% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -82589510.39% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -247461.779% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -345444.447% |
| Qrons Inc. | 420.00 USD | -454242757.143% |
| Skye Bioscience, Inc. | 11.94 Million USD | -15877.842% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -396901.812% |
| Rebus Holdings, Inc. | 5000.00 USD | -38156300.0% |
| CSL Limited | 38.02 Billion USD | 94.982% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -3520.083% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -4811.113% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -26324.971% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -2498551.02% |
| SQZ Biotechnologies Company | 107.18 Million USD | -1679.899% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -133124.677% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -2636284.993% |
| Mesoblast Limited | 667.9 Million USD | -185.644% |
| Marizyme, Inc. | 22.01 Million USD | -8565.971% |
| Genus plc | 1.02 Billion USD | -85.423% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -140350.973% |
| Pharming Group N.V. | 462.85 Million USD | -312.186% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -57485.665% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -382198.778% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -304177.512% |
| ContraFect Corporation | 20.67 Million USD | -9125.881% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -488625.965% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -499098.016% |
| IMV Inc. | 31.33 Million USD | -5988.699% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -45915.675% |
| MultiCell Technologies, Inc. | 126.22 USD | -1511503623.657% |
| ONE Bio Corp. | 70.08 Million USD | -2622.132% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -202926.746% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -1384.569% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -441817.566% |
| Q BioMed Inc. | 3.51 Million USD | -54168.547% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -5323.179% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -730090.564% |
| Biomind Labs Inc. | 73.81 Thousand USD | -2584356.576% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -327.466% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -131578.864% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -6256.232% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -69367.854% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -73187.605% |
| GB Sciences, Inc. | 103.44 Thousand USD | -1844237.89% |
| Alpha Cognition Inc. | 2.45 Million USD | -77701.294% |
| HST Global, Inc. | 1526.00 USD | -125020869.856% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -193005.64% |
| Halberd Corporation | 10.13 Thousand USD | -18831407.255% |
| Enzolytics Inc. | 361.7 Million USD | -427.45% |
| Agentix Corp. | 261.39 Thousand USD | -729769.315% |
| Resverlogix Corp. | 8.11 Million USD | -23409.797% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -101494.351% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 58.0% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -3899.455% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -298157.188% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -8374510.421% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -21218.437% |
| AVAX Technologies, Inc. | 7.37 Million USD | -25761.182% |
| Zenith Capital Corp. | 7410.00 USD | -25746458.704% |
| Genscript Biotech Corporation | 3.38 Billion USD | 43.662% |
| Ember Therapeutics, Inc. | 184.00 USD | -1036858595.652% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -592747.865% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -729847.506% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -205492.692% |
| Kadimastem Ltd | 2.3 Million USD | -82701.812% |
| Helix BioMedix, Inc. | 3.02 Million USD | -62966.637% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -3341442.018% |
| LadRx Corporation | 2.3 Million USD | -82565.405% |
| Cell Source, Inc. | 195.17 Thousand USD | -977412.028% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -539415.917% |
| NovAccess Global Inc. | 62.24 Thousand USD | -3064769.554% |
| Affymax, Inc. | 7.44 Million USD | -25532.406% |
| Itoco Inc. | 1.4 Million USD | -136165.849% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -1994338.462% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -1799730.189% |
| Mobile Lads Corp. | 52.00 USD | -3668884515.385% |
| CytoDyn Inc. | 11.13 Million USD | -17032.004% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -1334301.141% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -10670034.228% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -494832.174% |
| SYBLEU INC | 330.46 Thousand USD | -577208.544% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -465878.868% |
| International Stem Cell Corporation | 5.39 Million USD | -35295.547% |
| Bioxytran, Inc. | 137.63 Thousand USD | -1386014.3% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -12617.248% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -11407.449% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -2414862.025% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -220539.615% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -25280.072% |
| Neutra Corp. | 2851.00 USD | -66917472.781% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -5787.243% |
| PureTech Health plc | 693.97 Million USD | -174.913% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -23537.702% |
| IXICO plc | 15.84 Million USD | -11941.351% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -22935.74% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -1746.444% |
| CSL Limited | 38.02 Billion USD | 94.982% |
| Cellectis S.A. | 333.99 Million USD | -471.213% |